A detailed history of Barclays PLC transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Barclays PLC holds 545,008 shares of BBIO stock, worth $14.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
545,008
Previous 545,008 -0.0%
Holding current value
$14.4 Million
Previous $13.9 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$23.91 - $31.3 $3.15 Million - $4.12 Million
131,743 Added 31.88%
545,008 $13.9 Million
Q2 2024

Aug 14, 2024

BUY
$23.0 - $31.04 $186,231 - $251,330
8,097 Added 2.0%
413,265 $10.5 Million
Q1 2024

May 15, 2024

SELL
$27.35 - $40.45 $9.21 Million - $13.6 Million
-336,870 Reduced 45.4%
405,168 $12.5 Million
Q4 2023

Feb 15, 2024

BUY
$24.02 - $43.89 $6.26 Million - $11.4 Million
260,598 Added 54.13%
742,038 $30 Million
Q3 2023

Nov 07, 2023

SELL
$16.89 - $35.01 $1.82 Million - $3.77 Million
-107,724 Reduced 18.28%
481,440 $12.7 Million
Q2 2023

Aug 03, 2023

SELL
$13.29 - $18.01 $1.09 Million - $1.47 Million
-81,715 Reduced 12.18%
589,164 $10.1 Million
Q1 2023

May 04, 2023

SELL
$7.17 - $18.55 $3.81 Million - $9.85 Million
-531,006 Reduced 44.18%
670,879 $11.1 Million
Q4 2022

Feb 13, 2023

BUY
$6.74 - $11.52 $5.9 Million - $10.1 Million
875,468 Added 268.21%
1,201,885 $9.16 Million
Q3 2022

Nov 03, 2022

BUY
$7.94 - $12.36 $2.36 Million - $3.67 Million
296,979 Added 1008.83%
326,417 $3.24 Million
Q2 2022

Aug 12, 2022

SELL
$5.21 - $12.14 $68,501 - $159,616
-13,148 Reduced 30.87%
29,438 $268,000
Q1 2022

May 16, 2022

SELL
$7.34 - $17.16 $1.11 Million - $2.6 Million
-151,488 Reduced 78.06%
42,586 $432,000
Q4 2021

Feb 14, 2022

BUY
$11.38 - $53.41 $1.19 Million - $5.58 Million
104,508 Added 116.68%
194,074 $3.24 Million
Q3 2021

Nov 09, 2021

BUY
$46.87 - $64.24 $1.24 Million - $1.71 Million
26,546 Added 42.12%
89,566 $4.2 Million
Q2 2021

Aug 13, 2021

SELL
$46.47 - $63.93 $1.73 Million - $2.38 Million
-37,199 Reduced 37.12%
63,020 $3.84 Million
Q1 2021

May 13, 2021

BUY
$55.47 - $72.35 $3.54 Million - $4.61 Million
63,771 Added 174.96%
100,219 $6.17 Million
Q4 2020

Feb 11, 2021

BUY
$38.38 - $71.11 $118,056 - $218,734
3,076 Added 9.22%
36,448 $2.59 Million
Q3 2020

Nov 12, 2020

SELL
$27.2 - $42.19 $329,555 - $511,174
-12,116 Reduced 26.64%
33,372 $1.25 Million
Q2 2020

Aug 12, 2020

BUY
$22.22 - $35.69 $358,275 - $575,465
16,124 Added 54.91%
45,488 $1.48 Million
Q1 2020

May 13, 2020

BUY
$16.11 - $36.23 $52,035 - $117,022
3,230 Added 12.36%
29,364 $851,000
Q4 2019

Feb 10, 2020

BUY
$17.96 - $46.63 $223,260 - $579,657
12,431 Added 90.72%
26,134 $916,000
Q3 2019

Nov 14, 2019

SELL
$20.13 - $32.38 $73,092 - $117,571
-3,631 Reduced 20.95%
13,703 $294,000
Q2 2019

Aug 14, 2019

BUY
$26.97 - $27.55 $467,497 - $477,551
17,334 New
17,334 $467,000

Others Institutions Holding BBIO

About BridgeBio Pharma, Inc.


  • Ticker BBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 148,246,000
  • Market Cap $3.93B
  • Description
  • BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...
More about BBIO
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.